Camostat Mesylate

DRUG4 trials

Sponsors

Yale University, Assistance Publique - Hôpitaux de Paris, Seoul National University Hospital, Odense University Hospital

Conditions

COVID-19Camostat MesylateCardiovascular ComplicationChronic Kidney Disease(CKD)CoagulopathyCovid19Fontan OperationProtein-Losing Enteropathy

Phase 1

The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications

WithdrawnNCT04435015

Yale UniversityCardiovascular Complication, Coagulopathy, COVID-19

Start: 2021-11-30End: 2021-12-31Updated: 2022-05-18

Phase 2

Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation

CompletedNCT05474664

Seoul National University HospitalCamostat Mesylate, Fontan Operation, Protein-Losing Enteropathy

Start: 2022-10-03End: 2024-10-08Updated: 2024-12-03

Effect Camostat for Kidney Protection in Chronic Kidney Disease

RecruitingNCT06794593

Odense University HospitalChronic Kidney Disease(CKD)

Start: 2024-11-21End: 2027-02-28Target: 40Updated: 2025-01-27

Phase 3

CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients

TerminatedNCT04608266

Assistance Publique - Hôpitaux de ParisCovid19

Start: 2020-12-03End: 2021-12-02Updated: 2022-02-10

Related Papers

Phase 2 Open-label, Single-arm, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Camostat Mesylate in Patients with Protein-losing Enteropathy After Fontan Operation

Pediatric Cardiology2025-04-14

A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.

2022-12-1418 citations